678 filings
Page 4 of 34
6-K
mycc3szgavs8p64
8 Mar 23
Current report (foreign)
7:11pm
6-K
v0i6s5
6 Mar 23
Current report (foreign)
7:09am
6-K
s5i6w 4zw
28 Feb 23
Current report (foreign)
7:02am
6-K
ujxey
16 Feb 23
RedHill Announces Positive MHRA Meeting and Planned
8:01am
6-K
2z2tz9h9q3xwn45jdzk
15 Feb 23
RedHill Biopharma Announces Positive FDA Meeting
7:02am
6-K
nnv4 wl7c80vv
6 Feb 23
RedHill Biopharma and HealthCare Royalty Agree to
7:02am
6-K
vzu1o
26 Jan 23
RedHill Receives USPTO Notice of Allowance for a Patent Covering Phase 3-stage RHB-204 for the Treatment of NTM Disease
7:02am
6-K
eind0dodk4dlmxdm
25 Jan 23
Current report (foreign)
9:15am
6-K
9ivjhxtq7vwayir
24 Jan 23
Current report (foreign)
9:00am
6-K
wd21 c8u7a2ch
3 Jan 23
RedHill Announces Publication of Positive Phase 2 Study
7:02am
6-K/A
dxocsp2hny52v1b
27 Dec 22
Current report (foreign) (amended)
7:00am
6-K
4ta p2wm1
20 Dec 22
Current report (foreign)
7:00am
6-K
7uh315 65r
12 Dec 22
Current report (foreign)
7:00am
6-K
b40wruktvnnap
6 Dec 22
Current report (foreign)
1:38pm
6-K
7boeqq0
5 Dec 22
Current report (foreign)
4:24pm
6-K
nq4e75i ztz4q42
5 Dec 22
RedHill’s Aemcolo® Granted FDA QIDP 5-Year Exclusivity Extension
7:03am
6-K
cnahqs0xwdty oyilux3
2 Dec 22
Current report (foreign)
9:00am
6-K
9rekp2l0c07ss9c33
1 Dec 22
Current report (foreign)
4:01pm
6-K
wb6onq3qtda
29 Nov 22
RedHill Biopharma Announces Q3/22 Results and Non-binding agreement in principle reached with HCR on sale of Movantik to extinguish all debt
8:05am
6-K
cmasy1w58e41 s59
17 Nov 22
RedHill Biopharma Announces Positive New Data with Opaganib for Nuclear Radiation Injury
8:32am